Skip to main content
. 2012 Nov 12;26(6):414–422. doi: 10.3341/kjo.2012.26.6.414

Fig. 1.

Fig. 1

Mean logarithm of minimum angular resolution (logMAR) visual improvement in patients with the LOC387715 genotype treated with bevacizumab (black line, TT genotype; grey line, GT genotype; broken line, GG genotype) over a 12 month follow-up period. Visual improvement was greatest in the LOC387715 TT genotype group compared to other groups, at both six months (p = 0.037) and 12 months (p = 0.058) post-treatment.